Cedars-Sinai Medical Center, Los Angeles, CA, USA.
BMC Musculoskelet Disord. 2010 Apr 8;11:66. doi: 10.1186/1471-2474-11-66.
BACKGROUND: There are no standard criteria for defining or assessing severity of fibromyalgia (FM) as a condition as fibromyalgia is associated with multiple symptom domains. The objective of this study was to evaluate whether patient self-reported severity of FM is associated with severity of pain and sleep interference and the presence of core co-morbidities. METHODS: We recruited individuals >or= 18 years of age with a clinician-confirmed diagnosis of FM >or= 3 months and a current pain rating >2 on a 0-10 numeric rating scale (NRS). Patients completed a questionnaire by mail in which they self-rated their FM severity (very mild, mild, moderate, and severe), their current pain severity and extent of sleep interference (NRS; mild, 0-3; moderate, 4-6, severe, 7-10), and provided information (yes/no) on the presence of core comorbidities (symptoms of depression, anxiety, sleep problems, back pain, neck pain) and medication use for FM. The core symptoms of FM were stratified to assist with patient characterization. Analysis of variance (ANOVA) was used to explore the relationship between self-reported FM severity and continuous variables (pain severity and sleep interference), and Mantel-Haenszel chi-square analysis was used to evaluate the trend in the proportions of patients reporting use of medications and core symptoms of FM by severity of FM. To complement patient-reported FM severity and to understand physicians' perspectives, a survey was performed among 28 physician specialists (rheumatology, neurology, anesthesiology/pain management, family practice, internal medicine, and psychiatry) to determine what they assessed when evaluating FM severity in clinical practice. RESULTS: The population (N = 129) of FM patients was predominantly female (89.1%), with a mean age of 49.4 +/- 11.0 years, and 81.4% reported duration >or= 2 years. Self-reported FM severity was moderate/severe in 86.0% of patients; mean current pain score was 6.40 +/- 2.19 (moderate), and mean sleep interference score was 7.28 +/- 2.23 (severe). Greater FM severity was significantly associated with higher levels of current pain and sleep interference (p < 0.0001), the proportion of patients reporting FM medication use (p = 0.0001), and the presence of core comorbidities (p < 0.05). Pain, functional disability, and fatigue severity were ranked as the top three criteria by the highest proportion of physicians when evaluating FM severity. CONCLUSION: With higher self-reported FM severity, patients have greater pain and sleep interference as well as increased frequency of core comorbidities. Further investigation into understanding FM severity is warranted.
背景:由于纤维肌痛(FM)与多个症状领域相关,因此尚无定义或评估其严重程度的标准标准。本研究的目的是评估患者自我报告的 FM 严重程度是否与疼痛和睡眠干扰的严重程度以及核心合并症的存在相关。
方法:我们招募了年龄在 18 岁及以上、有临床医生确诊的 FM 病史至少 3 个月且目前疼痛评分在 0-10 数字评定量表(NRS)上大于 2 的患者。患者通过邮件完成一份调查问卷,自我评估 FM 严重程度(非常轻微、轻微、中度和严重)、当前疼痛严重程度和睡眠干扰程度(NRS;轻度,0-3;中度,4-6,重度,7-10),并提供有关核心合并症(抑郁、焦虑、睡眠问题、背痛、颈痛症状)和 FM 用药的存在与否的信息(是/否)。将 FM 的核心症状分层以帮助患者进行特征描述。方差分析(ANOVA)用于探索自我报告的 FM 严重程度与连续变量(疼痛严重程度和睡眠干扰)之间的关系,Mantel-Haenszel 卡方分析用于评估按 FM 严重程度报告使用药物和 FM 核心症状的患者比例的趋势。为了补充患者报告的 FM 严重程度并了解医生的观点,对 28 名专科医生(风湿病学、神经病学、麻醉学/疼痛管理、家庭实践、内科和精神病学)进行了一项调查,以确定他们在临床实践中评估 FM 严重程度时评估了什么。
结果:FM 患者人群(N=129)主要为女性(89.1%),平均年龄为 49.4±11.0 岁,81.4%的患者报告病程≥2 年。86.0%的患者自我报告的 FM 严重程度为中度/重度;当前疼痛评分的平均值为 6.40±2.19(中度),睡眠干扰评分的平均值为 7.28±2.23(重度)。FM 严重程度越高,当前疼痛和睡眠干扰的程度越高(p<0.0001),报告使用 FM 药物治疗的患者比例越高(p=0.0001),以及核心合并症的存在(p<0.05)。疼痛、功能障碍和疲劳严重程度是医生在评估 FM 严重程度时排名最高的三个标准。
结论:随着自我报告的 FM 严重程度增加,患者的疼痛和睡眠干扰加剧,核心合并症的发生频率也增加。需要进一步研究以了解 FM 严重程度。
BMC Musculoskelet Disord. 2010-4-8
Health Qual Life Outcomes. 2011-8-22
Clin Rheumatol. 2013-2-27
Clin Exp Rheumatol. 2016
Arthritis Res Ther. 2016-3-16
Evid Based Complement Alternat Med. 2013-11-20
PLoS One. 2013-9-30
Evid Based Complement Alternat Med. 2013-6-4
Arthritis Res Ther. 2008
Patient Educ Couns. 2008-10
Arthritis Rheum. 2008-7-15
Health Qual Life Outcomes. 2008-1-22
J Occup Environ Med. 2008-1
Scand J Rheumatol. 2007